Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Preclinical research"'
Autor:
Peter Májek, Ruochen Jia, Michael Schuster, Leon Kutzner, Anna Koren, André C. Müller, Joanna I. Loizou, Robert Kralovics, Christoph Bock, Stefan Kubicek, Kathrin Runggatscher
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 7, Pp 1-10 (2021)
Blood Cancer Journal
Blood Cancer Journal
Mutations of calreticulin (CALR) are the second most prevalent driver mutations in essential thrombocythemia and primary myelofibrosis. To identify potential targeted therapies for CALR mutated myeloproliferative neoplasms, we searched for small mole
Autor:
Leonard H. van den Berg, Philip Van Damme, Caroline Ingre, Philippe Corcia, Ruben P A van Eijk, Christopher J McDermott, Evy Reviers, Orla Hardiman, Adriano Chiò, Mònica Povedano, Kit C.B. Roes, Tessa Kliest, Ammar Al-Chalabi, Markus Weber, Michael A van Es
Publikováno v:
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 21, 496-501
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 21, 7-8, pp. 496-501
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 21, 7-8, pp. 496-501
A change in our current approach toward drug development is required to improve the likelihood of finding effective treatment for patients with amyotrophic lateral sclerosis (ALS). The aim of the Treatment Research Initiative to Cure ALS (TRICALS) is
Autor:
Mithun Santra, Deeksha Katoch, Manni Luthra-Guptasarma, Maryada Sharma, Sahil Jain, Uma Nahar Saikia, Mangat R Dogra
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Scientific Reports
Scientific Reports
Induction of posterior vitreous detachment (PVD) by pharmacologic vitreolysis has been largely attempted through the use of enzymatic reagents. Ocriplasmin has been the only FDA-approved clinical reagent so far. Several adverse effects of ocriplasmin
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
Scientific Reports
Scientific Reports
The most challenging issue for breast cancer (BC) patients is metastasis to other organs because current therapies do not prevent or eliminate metastatic BC. Here, we show that SM-164, a small molecule inhibitor, which degrades inhibitor of apoptosis
Autor:
Phillip P. Chan, Pamela O'sullivan, Vincent J. Capponi, Timothy J. Kovacs, Kathryn Dawson, Maryann Gruda, Karl-Gustav Ruggeberg, Thomas D. Golobish
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
Scientific Reports
Scientific Reports
Mycotoxins, such as aflatoxin B1 (AFB1), pose a serious threat as biological weapons due to their high toxicity, environmental stability, easy accessibility and lack of effective therapeutics. This study investigated if blood purification therapy wit
Autor:
Alan P. Kozikowski, Sida Shen
Publikováno v:
Expert Opin Ther Pat
INTRODUCTION: Histone deacetylase 6 (HDAC6) is unique in comparison with other zinc-dependent HDAC family members. An increasing amount of evidence from clinical and preclinical research demonstrates the potential of HDAC6 inhibition as an effective
Autor:
Rodney C. Diaz, Oliver Y. Chin
Publikováno v:
Current Opinion in Otolaryngology & Head & Neck Surgery. 27:381-386
Purpose of review Increasing awareness and prevalence of disorders in hearing and balance have placed emphasis on treatment strategies. With the rapid evolution in molecular, gene, and nanotechnology, alternate delivery methods have advanced intracoc
Autor:
Nanna Skeltved, Mads Daugaard, Maj Sofie Ørum-Madsen, Thomas Mandel Clausen, Mie A. Nordmaj, Swati Choudhary, Zhang Yang, Robert Dagil, Kaare V. Grunddal, Emilie S. Sachse, Thor G. Theander, Weihua Tian, Ali Salanti, Morten Nielsen, Igor Moskalev, Sayit Mahmut Erdoğan, Morgan E. Roberts, Anne Poder Andersen, Tobias Gustsavsson
Publikováno v:
Cell Death & Disease
Nordmaj, M A, Roberts, M E, Sachse, E S, Dagil, R, Andersen, A P, Skeltved, N, Grunddal, K V, Erdoğan, S M, Choudhary, S, Gustavsson, T, Ørum-madsen, M S, Moskalev, I, Tian, W, Yang, Z, Clausen, T M, Theander, T G, Daugaard, M, Nielsen, M A & Salanti, A 2021, ' Development of a bispecific immune engager using a recombinant malaria protein ', Cell Death & Disease, vol. 12, no. 4, 353 . https://doi.org/10.1038/s41419-021-03611-0
Cell Death and Disease, Vol 12, Iss 4, Pp 1-11 (2021)
Nordmaj, M A, Roberts, M E, Sachse, E S, Dagil, R, Andersen, A P, Skeltved, N, Grunddal, K V, Erdoğan, S M, Choudhary, S, Gustavsson, T, Ørum-madsen, M S, Moskalev, I, Tian, W, Yang, Z, Clausen, T M, Theander, T G, Daugaard, M, Nielsen, M A & Salanti, A 2021, ' Development of a bispecific immune engager using a recombinant malaria protein ', Cell Death & Disease, vol. 12, no. 4, 353 . https://doi.org/10.1038/s41419-021-03611-0
Cell Death and Disease, Vol 12, Iss 4, Pp 1-11 (2021)
As an immune evasion and survival strategy, the Plasmodium falciparum malaria parasite has evolved a protein named VAR2CSA. This protein mediates sequestration of infected red blood cells in the placenta through the interaction with a unique carbohyd
Publikováno v:
Neuropsychopharmacology
Binge-eating disorder (BED) is characterized by recurring episodes of excessive consumption of palatable food and an increased sensitivity to food cues. Patients with BED display an addiction-like symptomatology and the dopamine system might be a pot
Autor:
Danylo Kaminskyy, Roman Lesyk, Marcin L. Leja, Jan Gmiński, Konrad A. Szychowski, Tadeusz Pomianek, Jakub Tobiasz, Maciej Wnuk, Anna Kryshchyshyn
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-16 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-16 (2019)
4-thiazolidinones, which are privileged structures in medicinal chemistry, comprise the well-known class of heterocycles and are a source of new drug-like compounds. Undoubtedly, the 5-bulky-substituted-2,4-thiazolidinediones - a class of antihypergl